Literature DB >> 27867948

Supra-therapeutic plasma concentrations of haloperidol induce moderate inhibition of lipopolysaccharide-induced interleukin-8 release in human monocytes.

Herbert Bosshart1.   

Abstract

BACKGROUND: The clinical use of antipsychotics and mood-stabilizing drugs with proven efficacy is largely determined by the occurrence of treatment-emergent adverse events and routine clinical chemistry and haematology data, which together define the safety and tolerability profile of these psychopharmaceuticals. Whereas the effects of mood-stabilizing drugs on functional properties of blood cells have been poorly investigated, the effects of antipsychotics have received more attention. Such studies have yielded conflicting results. This study examined the effects of the mood-stabilizing drugs carbamazepine and valproic acid and of the antipsychotic drugs olanzapine, risperidone and haloperidol on the production of the pro-inflammatory chemokine interleukin-8 (IL-8), which is released from human monocytes when activated by Gram-negative lipopolysaccharide (LPS).
METHODS: Peripheral human whole blood was diluted with Roswell Park Memorial Institute (RPMI) cell culture medium and stimulated with LPS. Accumulating IL-8 was quantified in the supernatant with an adapted enzyme-linked immunosorbent assay (ELISA) and the results correlated to the number of monocytes at venipuncture.
RESULTS: At supra-therapeutic concentrations of 100 µM, haloperidol inhibited the LPS-induced release of IL-8 in peripheral human monocytes moderately, whereas olanzapine, risperidone, carbamazepine and valproic acid showed no such effect.
CONCLUSIONS: The results suggest that these mood-stabilizing drugs and antipsychotics are endowed with clinically favorable inertness rather than pro-inflammatory properties.

Entities:  

Keywords:  Lipopolysaccharide (LPS); carbamazepine; haloperidol; interleukin-8 (IL-8); monocytes; olanzapine; risperidone; valproic acid

Year:  2016        PMID: 27867948      PMCID: PMC5107389          DOI: 10.21037/atm.2016.10.56

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  41 in total

1.  Antioxidant activity applying an improved ABTS radical cation decolorization assay.

Authors:  R Re; N Pellegrini; A Proteggente; A Pannala; M Yang; C Rice-Evans
Journal:  Free Radic Biol Med       Date:  1999-05       Impact factor: 7.376

2.  Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia.

Authors:  J Kowalski; P Blada; K Kucia; A Madej; Z S Herman
Journal:  Schizophr Res       Date:  2001-07-01       Impact factor: 4.939

3.  Endocytosis of heparin-binding protein (CAP37) is essential for the enhancement of lipopolysaccharide-induced TNF-alpha production in human monocytes.

Authors:  M Heinzelmann; A Platz; H Flodgaard; H C Polk; F N Miller
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

4.  Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication.

Authors:  O V Olesen; K Linnet
Journal:  Ther Drug Monit       Date:  1999-02       Impact factor: 3.681

5.  Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone.

Authors:  Jean-Pierre Lindenmayer; Kathleen Jarboe; Cynthia A Bossie; Young Zhu; Angelika Mehnert; Robert Lasser
Journal:  Int Clin Psychopharmacol       Date:  2005-07       Impact factor: 1.659

Review 6.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

7.  Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology.

Authors:  Xiang Yang Zhang; Dong Feng Zhou; Pei Yan Zhang; Gui Ying Wu; Lian Yuan Cao; Yu Cun Shen
Journal:  Schizophr Res       Date:  2002-10-01       Impact factor: 4.939

8.  Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers.

Authors:  M Maes; E Bosmans; J Calabrese; R Smith; H Y Meltzer
Journal:  J Psychiatr Res       Date:  1995 Mar-Apr       Impact factor: 4.791

9.  A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group.

Authors:  R H Mattson; J A Cramer; J F Collins
Journal:  N Engl J Med       Date:  1992-09-10       Impact factor: 91.245

10.  Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.

Authors:  Xiang Yang Zhang; Dong Feng Zhou; Lian Yuan Cao; Pei Yan Zhang; Gui Ying Wu; Yu Cun Shen
Journal:  J Clin Psychiatry       Date:  2004-07       Impact factor: 4.384

View more
  2 in total

Review 1.  Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics.

Authors:  Samantha Alvarez-Herrera; Raúl Escamilla; Oscar Medina-Contreras; Ricardo Saracco; Yvonne Flores; Gabriela Hurtado-Alvarado; José Luis Maldonado-García; Enrique Becerril-Villanueva; Gilberto Pérez-Sánchez; Lenin Pavón
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-21       Impact factor: 5.555

2.  Pro-oxidant and degenerative effects of haloperidol under inflammatory conditions in rat; the involvement of SIRT1 and NF-κB signaling pathways.

Authors:  Saman Bahrambeigi; Mahsa Khatamnezhad; Siamak Asri-Rezaei; Bahram Dalir-Naghadeh; Shahram Javadi; Navideh Mirzakhani
Journal:  Vet Res Forum       Date:  2021-06-15       Impact factor: 1.054

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.